Ironwood Pharmaceuticals, Inc. IRWD · NASDAQ
$3.59 -4.52% (-$0.17)
Summary
71 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 33 USD is left as net profit.
- It earns 58 USD a year on every 100 USD of invested capital.
- The share price is below the Bulios Fair Price.
What to watch
- Revenue fell by 10% a year over the last 3 years.
- It missed profit estimates 5 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapPrice against the Bulios Fair Price
P/E against its own last 5 years
P/E against the industry (Drug Manufacturers - Specialty & Generic)
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 4.6 USD for 1 USD of yearly profit. Over the last five years it was 211.9 USD on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 5.3% a year over 5 years. Over the last 3 years it fell by 10% a year. Earnings per share fell by 46% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 0.2 USD
- Research and development 23 USD
- Sales and administration 17 USD
- Taxes and other 27 USD
- Net profit 33 USD
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 0.0 USD
Out of every 100 USD of revenue, 33 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.1 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 11
- Hold 16
- Sell 3
Today's price within the analysts' price targets
The average target of $6.68 is 86% above today's price. 37% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Collaborative Arrangements 99%
- Collaborative arrangement, collaboration and license agreements 0.6%
- Royalty 0.1%
- Collaborative arrangement, other agreements 0.0%
By region
- North America 99%
- Europe and Other 1.2%
Collaborative Arrangements brings in 99% of revenue. Collaborative arrangement, collaboration and license agreements grew fastest, by 23% a year.
Segments in detail